Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients|
van de Wetering, M.
|Citation:||Supportive Care in Cancer, 2013; 21(11):3191-3207|
|Deborah P. Saunders, Joel B. Epstein, Sharon Elad, Justin Allemano, Paolo Bossi, Marianne D. van de Wetering, Nikhil G. Rao, Carin Potting, Karis K. Cheng, Annette Freidank, Michael T. Brennan, Joanne Bowen, Kristopher Dennis, Rajesh V. Lalla|
|Abstract:||PURPOSE The aim of this project was to develop clinical practice guidelines on the use of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the prevention and management of oral mucositis (OM) in cancer patients. METHODS A systematic review of the available literature was conducted. The body of evidence for the use of each agent, in each setting, was assigned a level of evidence. Based on the evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, or no guideline possible. RESULTS A recommendation was developed in favor of patient-controlled analgesia with morphine in hematopoietic stem cell transplant (HSCT) patients. Suggestions were developed in favor of transdermal fentanyl in standard dose chemotherapy and HSCT patients and morphine mouth rinse and doxepin rinse in head and neck radiation therapy (H&N RT) patients. Recommendations were developed against the use of topical antimicrobial agents for the prevention of mucositis. These included recommendations against the use of iseganan for mucositis prevention in HSCT and H&N RT and against the use of antimicrobial lozenges (polymyxin–tobramycin–amphotericin B lozenges/paste and bacitracin–clotrimazole–gentamicin lozenges) for mucositis prevention in H&N RT. Recommendations were developed against the use of the mucosal coating agent sucralfate for the prevention or treatment of chemotherapy-induced or radiation-induced OM. No guidelines were possible for any other agent due to insufficient and/or conflicting evidence. CONCLUSION Additional well-designed research is needed on prevention and management approaches for OM.|
Mucosal coating agents
|Description:||For the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) Corrected by: Erratum: 10.1007/s00520-014-2542-3 The original version of this paper unfortunately contains errors. Morphine 2 % rinse, should have read as Morphine 0.2 % rinse.|
|Rights:||© 2013 Springer-Verlag Berlin Heidelberg.|
|Appears in Collections:||Aurora harvest|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.